Ramucirumab‐containing chemotherapy for patients with gastrointestinal neuroendocrine carcinoma refractory/intolerant to platinum‐based chemotherapy: A multicenter observational retrospective study (WJOG13420G)
International Journal of Cancer · 2025
DOI: 10.1002/ijc.70053 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift International Journal of Cancer, 2025. Verfasst von Yuki Matsubara und 29 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Oncology, Aichi Cancer Center Hospital, Nagoya, Aichi Prefecture, Japan. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Antineoplastic Combined Chemotherapy Protocols, Carcinoma, Neuroendocrine, Stomach Neoplasms. Die Arbeit nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Eli Lilly Japan K.K., Japan., Eli Lilly Japan.
Themen: Onkologische Pflege
Abstract (Originalsprache)
No standard second‐line chemotherapy has been established for gastrointestinal neuroendocrine carcinoma (NEC). This study aimed to determine whether ramucirumab (RAM) is a treatment candidate in this setting. We retrospectively collected data from patients with gastric and colorectal NEC who received second‐line chemotherapy following platinum‐based chemotherapy. The pathological diagnosis of NEC was confirmed centrally according to the World Health Organization 2019 classification. We compared the clinical outcomes between second‐ or later‐line chemotherapy in the RAM group and second‐line chemotherapy in the non‐RAM group. One‐hundred patients diagnosed with NEC by central pathological review were studied. The RAM and non‐RAM groups included 44 (gastric/colorectal cancer, 34/10) and 56 (37/19) patients, respectively. In the RAM group, 68% of patients received RAM as second‐line chemotherapy. RAM was most frequently combined with weekly paclitaxel for gastric NEC and FOLFIRI for colorectal NEC. The RAM group showed better trends in overall survival and progression‐free survival than the non‐RAM group, with a median of 9.0 versus 5.6 months and 4.3 versus 1.8 months, respectively (hazard ratios [HR]: 0.75 [95% CI: 0.45–1.28] and 0.45 [0.27–0.75]). Efficacy was more pronounced in gastric NEC (PFS HR: 0.32, OS HR: 0.56) compared to colorectal NEC (PFS HR: 0.82, OS HR: 1.47). The objective response rate was significantly higher in the RAM group (44%) than in the non‐RAM group (6%), with notably higher responses observed in patients receiving paclitaxel plus RAM (62%). This study suggested that RAM‐containing chemotherapy, especially paclitaxel plus RAM for gastric NEC, seems promising and should be further investigated.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Clinical Oncology, Aichi Cancer Center Hospital, Nagoya, Aichi Prefecture, Japan.
- Department of Gastroenterology and Gastrointestinal Oncology, National Cancer Center Hospital East, Kashiwa, Chiba Prefecture, Japan.
- Department of Pathology and Molecular Diagnostics, Aichi Cancer Center Hospital, Nagoya, Aichi Prefecture, Japan.
- Department of Gastrointestinal Medical Oncology, National Cancer Center Hospital, Tokyo, Japan.
- Department of Hematology and Medical Oncology, Kanagawa Cancer Center, Yokohama, Kanagawa Prefecture, Japan.
- Department of Medical Oncology, Osaka International Cancer Institute, Osaka City, Osaka Prefecture, Japan.
ORCID-Profile: Toshiki Masuishi, Hidekazu Hirano, Takaya Shimura, Isao Oze, Kei Muro
Förderung
- Eli Lilly Japan K.K., Japan.
- Eli Lilly Japan
Zitieren
APA
Matsubara, Y., Masuishi, T., Hosoda, W., Hirano, H., Mishima, S., Takahashi, H., Otsuka, T., Kawasaki, K., Kawakami, T., Yanagihara, K., Shimura, T., Komoda, M., Murayama, K., Minashi, K., Yamamoto, Y., Shinohara, Y., Nishina, S., Musha, N., Kato, K., …, & Muro, K. (2025). Ramucirumab‐containing chemotherapy for patients with gastrointestinal neuroendocrine carcinoma refractory/intolerant to platinum‐based chemotherapy: A multicenter observational retrospective study (WJOG13420G). International Journal of Cancer. https://doi.org/10.1002/ijc.70053
Vancouver
Matsubara Y, Masuishi T, Hosoda W, Hirano H, Mishima S, Takahashi H, et al. Ramucirumab‐containing chemotherapy for patients with gastrointestinal neuroendocrine carcinoma refractory/intolerant to platinum‐based chemotherapy: A multicenter observational retrospective study (WJOG13420G). International Journal of Cancer. 2025. doi:10.1002/ijc.70053
BibTeX
@article{Matsubara2025,
author = {Matsubara, Yuki and Masuishi, Toshiki and Hosoda, Waki and Hirano, Hidekazu and Mishima, Saori and Takahashi, Hiroyuki and Otsuka, Tomoyuki and Kawasaki, Kenta and Kawakami, Takeshi and Yanagihara, Kazuhiro and Shimura, Takaya and Komoda, Masato and Murayama, Kozue and Minashi, Keiko and Yamamoto, Yoshiyuki and Shinohara, Yudai and Nishina, Shinichi and Musha, Nobuyuki and Kato, Kyoko and Kawakami, Kentaro and Shinozaki, Katsunori and Tsuchihashi, Kenji and Ando, Takayuki and Kito, Yosuke and Makiyama, Akitaka and Mitani, Seiichiro and Hino, Kaori and Izawa, Naoki and Oze, Isao and Muro, Kei},
title = {Ramucirumab‐containing chemotherapy for patients with gastrointestinal neuroendocrine carcinoma refractory/intolerant to platinum‐based chemotherapy: A multicenter observational retrospective study (WJOG13420G)},
journal = {International Journal of Cancer},
year = {2025},
doi = {10.1002/ijc.70053}
}
EUVIMED